Introduction
The judgment of the Income Tax Appellate Tribunal (ITAT), Delhi Bench, in M/s. Translumina Therapeutics LLP vs. Pr. CIT, Dehradun (ITA No. 2520/Del/2017, Assessment Year 2012-13) is a seminal ruling on the scope of revisional jurisdiction under Section 263 of the Income-tax Act, 1961. The Tribunal quashed the Commissioner’s revision order, holding that the Assessing Officer (AO) had conducted a thorough enquiry into the deduction claimed under Section 80IC for manufacturing drug-eluting stents. The decision reinforces the principle that a mere difference of opinion with the AO’s conclusions does not render an assessment order “erroneous” or “prejudicial to the interest of revenue.” This commentary dissects the facts, legal reasoning, and implications of the ruling, emphasizing the procedural safeguards against arbitrary revisionary powers.
Facts of the Case
The assessee, M/s. Translumina Therapeutics LLP, set up a manufacturing unit at Pharma City, Selaqui, Uttarakhand, and commenced business on 22 June 2011. It was engaged in producing drug-coated coronary stents and their sterilized packing. For Assessment Year 2012-13, the assessee filed a return declaring nil income and claimed a deduction of Rs. 14,00,880 under Section 80IC of the Act. The AO completed the assessment under Section 143(3) on 18 March 2015, allowing the deduction after conducting detailed enquiries, including examination of books of accounts, tax audit reports, quantitative details, and a spot inspection by an Income Tax Inspector.
The Commissioner of Income Tax (CIT), Dehradun, invoked Section 263, alleging that the AO had not properly examined the admissibility of the deduction. The CIT argued that the drug-coating process did not constitute “manufacturing” as defined under Section 2(29BA) and that the assessee had not furnished the audit report in Form 10CCB or the list of drugs manufactured. The CIT set aside the assessment, directing a fresh enquiry. Aggrieved, the assessee appealed to the ITAT.
Reasoning of the Tribunal
The Tribunal’s reasoning is structured around two core issues: (a) the validity of the jurisdictional notice under Section 143(2), and (b) the sustainability of the revision under Section 263.
1. Validity of Jurisdictional Notice under Section 143(2):
The assessee contended that the assessment order was void ab initio because the jurisdictional AO at Dehradun had not issued a notice under Section 143(2) within the prescribed period. The Tribunal examined the procedural chronology: the assessee’s PAN database initially assigned jurisdiction to the Deputy/Assistant Commissioner of Income Tax, New Delhi. On 16 August 2013, the New Delhi AO issued a notice under Section 143(2). Subsequently, on 2 September 2013, the assessee requested transfer of jurisdiction to Dehradun, citing its principal place of business. The New Delhi AO transferred the records to the ACIT, Dehradun, who then assigned the case to ITO Ward 2(5), Dehradun, which completed the assessment on 18 March 2015.
The Tribunal held that the notice under Section 143(2) was validly issued by the AO having jurisdiction at the relevant time (New Delhi). The subsequent transfer under Sections 124 and 129 was lawful and did not vitiate the assessment. The Tribunal rejected the argument that the assessment was void, citing the decision in Micro Spacematrix Solutions Private Limited vs. ITO (ITA No. 669/Del/2012), which held that jurisdiction cannot be conferred by consent but must follow statutory procedure. Here, the procedure was correctly followed.
2. Sustainability of Revision under Section 263:
The Tribunal applied the settled legal principle that for an order to be revised under Section 263, it must be both “erroneous” and “prejudicial to the interest of revenue.” The CIT’s revision was based on two grounds: (a) the drug-coating process did not amount to manufacturing, and (b) the assessee failed to furnish Form 10CCB and the list of drugs.
The Tribunal meticulously analyzed the AO’s enquiry process. The AO had:
– Examined books of accounts and tax audit reports.
– Issued notices under Sections 142(1) and 133(6) to third parties.
– Conducted a spot inspection through an Inspector, whose report was considered.
– Reviewed the assessee’s technical submissions on the drug-coating process, which involved complex chemical transformation of raw materials into drug-eluting stents.
The Tribunal noted that the AO’s order reflected application of mind, as he had allowed the deduction after verifying the manufacturing process and compliance with Section 80IC conditions. The CIT’s disagreement with the AO’s conclusion did not make the order “erroneous.” The Tribunal emphasized that the CIT must demonstrate a tangible lapse in enquiry, not merely a perceived inadequacy.
3. Prospective Application of Explanation 2 to Section 263:
The Tribunal observed that Explanation 2 to Section 263, inserted by the Finance Act, 2015, with effect from 1 June 2015, was prospective. Since the assessment order was passed on 18 March 2015, the Explanation did not apply. Even if it had applied, the AO’s detailed enquiry would have satisfied the requirement of “proper enquiry.”
4. Manufacturing vs. Processing:
The Tribunal upheld the AO’s finding that drug-coating on stents constituted manufacturing under Section 2(29BA). The process involved chemical transformation, patent protection, and creation of a distinct product (drug-eluting stents) with different properties from raw materials. The CIT’s contrary view was a mere difference of opinion, not a basis for revision.
Conclusion
The ITAT quashed the CIT’s revision order, holding that the assessment was neither erroneous nor prejudicial to revenue. The Tribunal reinforced that revisional powers under Section 263 cannot be used to substitute the AO’s judgment with the CIT’s opinion, especially when the AO has conducted a thorough enquiry. The decision protects taxpayers from arbitrary revisionary actions and underscores the importance of documented enquiries in assessment proceedings. For professionals, this ruling is a robust defense against revisionary overreach, particularly in deduction claims involving technical manufacturing processes.